Vanguard reports 5.27% Ocugen stake in 13G
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Ocugen Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Ocugen Inc. common stock. Vanguard reports beneficial ownership of 16,475,562 shares, representing 5.27% of the class as of 12/31/2025.
Vanguard has shared voting power over 1,981,345 shares and shared dispositive power over 16,475,562 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control of Ocugen.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Ocugen (OCGN) does The Vanguard Group report?
How much voting power does Vanguard have in Ocugen (OCGN)?
Is Vanguard’s Ocugen (OCGN) position intended to influence control?
Who ultimately benefits from Vanguard’s Ocugen (OCGN) holdings?
What internal changes at Vanguard are mentioned in this Ocugen filing?
Who signed The Vanguard Group’s Schedule 13G for Ocugen (OCGN)?
AI-generated analysis. How Rhea-AI works. Not financial advice.